Valuation: Insmed Incorporated

Market Cap 23.87B 20.81B 19.21B 17.63B 33.5B 2,297B 34.07B 229B 89.84B 1,122B 89.61B 87.65B 3,869B P/E 2026 *
-42.3x
P/E 2027 * 187x
Enterprise Value 23.3B 20.32B 18.76B 17.21B 32.71B 2,243B 33.26B 223B 87.71B 1,095B 87.49B 85.57B 3,777B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 8.25x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.27%
1 week-2.69%
Current month+2.99%
1 month+12.22%
3 months-28.42%
6 months-32.82%
Current year-36.91%
1 week 107.33
Extreme 107.33
119.54
1 month 93.92
Extreme 93.92
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
07-08Fiscal year

Chief Executive Officer

32,097 0.0148%
07-05Fiscal year

Chief Technology Officer

36,906 0.0170%
06-24Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%-2.69%+7.77%+433.06% 23.87B
-1.39%-7.58%+54.00%+124.73% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
+1.76%-2.44%-17.13%-15.01% 22.86B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%-0.03%+38.19%-27.77% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
-0.39%-2.68%+21.87%+186.49% 14.02B
+2.49%+0.90%+72.02%+143.72% 12.38B
Average +2.85%+0.15%+55.85%+202.01% 25.16B
Weighted average by Cap. +2.12%+0.37%+53.32%+168.71%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.37B 1.25B 2.38B 163B 2.42B 16.27B 6.39B 79.81B 6.37B 6.23B 275B 2.78B 2.42B 2.23B 2.05B 3.9B 267B 3.96B 26.6B 10.45B 130B 10.42B 10.19B 450B
Net income -567M -495M -457M -419M -796M -54.59B -810M -5.44B -2.14B -26.67B -2.13B -2.08B -91.95B 92.12M 80.34M 74.15M 68.03M 129M 8.87B 132M 883M 347M 4.33B 346M 338M 14.93B
Net Debt -566M -493M -455M -418M -794M -54.43B -807M -5.42B -2.13B -26.59B -2.12B -2.08B -91.67B -983M -857M -791M -726M -1.38B -94.62B -1.4B -9.42B -3.7B -46.22B -3.69B -3.61B -159B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-15 US$109.81 -0.27% 2,116,538
26-07-14 US$110.11 +0.89% 1,848,330
26-07-13 US$109.14 -5.60% 2,825,240
26-07-10 US$115.61 -2.24% 2,931,618
26-07-09 US$118.26 +1.48% 3,167,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
110.11USD
Average target price
196.38USD
Spread / Average Target
+78.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock